4dmedical Ltd. · ASX:4DX
4dmedical — Shareholder Meeting (November 2024)
31 slides from 4dmedical's shareholder meeting presentation, Nov 20, 2024
Slide 1: The future of lung health
The future of lung health 4DMedical Limited (ASX:4DX) Annual General Meeting 20 November 2024 4DMedical Limited ABN 31 161 684 831
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by 4DMedical Limited (ACN 161 684 831) (Company or 4DMedical). This presentation contains summary information about the Company, its subsidiaries and the entities, businesses and assets they own and operate (Group) and their activities current as of 20
Slide 3: Overview
Overview a& 4DMedical
Slide 4: Agenda
Agenda 1. Opening & introductions 2. Chair’s address 3. CEO’s address 4. Procedural matters 5. Formal business 6. Closing remarks 4
Slide 5: Board of Directors – significant medical and commercial sector experience
Board of Directors – significant medical and commercial sector experience Key Advisors Dr DAVID J. SHULKIN MD Key Advisor Highly respected physician and health care LIL BIANCHI Dr ANDREAS FOURAS PhD Dr ROBERT A. FIGLIN MD executive, Dr Shulkin was previously the Secretary of the United States Depart
Slide 6: Chair’s address
Chair’s address LIL BIANCHI Non-Executive Chair Experienced contributor of business transformations for US listed technology companies with a beneficial technology product expertise in AI and SaaS offerings.
Slide 7: FY24 Financial Summary
FY24 Financial Summary • 4DMedical reported a net cash balance of $30.6 million at 30 June 2024, with zero debt. $30.6m $3.8m Cash reserves Operating Revenue (zero debt) +422% vs FY23 • Total operating revenue of $3.8 million, up 422% on pcp, with total income of $14.8 million including $11.0 in oth
Slide 8: CEO’s address
CEO’s address Dr ANDREAS FOURAS PhD Managing Director Award-winning aerospace engineer and innovator responsible for the conception and development of 4DMedical’s core technologies.
Slide 9: Global respiratory diagnostic market valued at US$31.4 billion per annum
Global respiratory diagnostic market valued at US$31.4 billion per annum Four existing lung diagnostic technologies account for 99% of all lung scans: Country Spend Procedures ($USD) Expenditure (USD $B) U.S.A 13,716M 73.5M 20 Others 4,964M 59.8M Germany 2,678M 20.3M Japan 1,905M 22.8M 15 Procedures
Slide 10: Current lung diagnostics are failing us
Current lung diagnostics are failing us Lung health screening Unexplained dyspnoea Burn Pits & DRRD (COPD, silicosis, black lung, lung cancer) (shortness of breath) (Deployment-related Respiratory Disease) COPD – 4th largest cause of $12.2bn cost of breathlessness in Australia2 >6million servi
Slide 11: Comprehensive chest diagnostics product suite
Comprehensive chest diagnostics product suite CT LVAS* XV LVAS* CT:VQ*** Pulmonary Hypertension XV Scanner^ VA Initiatives Assessment* Functional Coronary Lung Density Artery Analysis* Calcification* XV Technology Partnerships Lung Density Analysis — Lung Texture Inspiration* Analysis** Case Studies
Slide 12: A complete lung health solution
A complete lung health solution Pulmonary Structure Pulmonary Function Cardiovascular Total Solution Lung Density* XV LVAS®* CAC* Combined product Emphysema, HAA, Fissures Dynamic Ventilation Coronary Calcification/Heart suite Analysis (Fluoro) Disease Enabling access to key imaging modalities: CT,
Slide 13: Solving the clinical conundrum for doctors across multiple care areas
Solving the clinical conundrum for doctors across multiple care areas Clinical Conundrum in Clinical Tools Needed to Applications for Technologies in Clinical Lung Assessment Solve the Conundrum Practice A mismatch between clinical Functional lung analysis providing Unexplained dyspnoea Example tech
Slide 14: FY24 achievements – building the foundations
FY24 achievements – building the foundations Philips Expansion in AU Master Reseller Agreement executed US reimbursement & Commercial agreement Significant expansion of commercialisation signed with Jones commercial coverage Radiology in Adelaide across multiple sectors US Medicare in the la
Slide 15: Commercialisation strategy
Commercialisation strategy US Government US Commercial Global Partnerships Australia Enablers Philips Olympus I-MED Exclusive Non-exclusive Genentech Jones Radiology Reimbursement Nuance/Aidoc/Blackford Integral Diagnostics Sector Veterans Affairs Community-based Clinics Global Pharma Companies Comm
Slide 16: Philips overview
Philips overview Philips Healthcare – portfolio of businesses2 €18.2bn in sales (2023), ~70% in #1 or #2 positions; ~40% sales recurring revenue; ~70k employees 42% North America, 21% Western Europe, 9% other mature geographies, 28% growth geographies Personal health: Diagnosis & treatment: Connecte
Slide 17: Philips reseller agreement
Philips reseller agreement The Reseller Agreement The opportunity • Philips has long established and significant existing 1 partnership with both the VA and DoD, spanning 45 years • Philips & 4DMedical to work together to Background support the need for scalable, non-invasive • 50% of VA clinics usi
Slide 18: Procedural matters
Procedural matters a& 4DMedical
Slide 19: Formal business
Formal business a& 4DMedical
Slide 20: Items of business
Items of business Item 1: Financial Report, Directors’ Report and Auditors Report Item 2: Remuneration Report Item 3: Re-election of Director, Dr Robert A. Figlin Item 4: Issue of securities to Directors Item 5: Issue of securities to Directors in lieu of base directors’ fees – Ms Lil Bianchi and Dr
Slide 21: Formal business
Formal business Item 1: Financial Report, Directors’ Report and Auditors Report To receive and consider the Financial Report of the Company and its controlled entities and the Reports of the Directors and Auditor for the year ended 30 June 2024. 21
Slide 22: Formal business
Formal business Item 2: Remuneration Report To consider, and if thought fit, to pass, the following as an ordinary resolution: “That the Remuneration Report, as contained in the Directors’ Report for the year ended 30 June 2024, is adopted.” In Favour Against Proxy Discretion Abstain 15,628,689 8,14
Slide 23: Formal business
Formal business Item 3: Re-election of Director, Dr Robert A. Figlin To consider, and if thought fit, to pass, the following as an ordinary resolution: “That, for the purposes of clause 13.3(b) of the Constitution, ASX Listing Rule 14.4, and for all other purposes, Dr Robert A. Figlin, a non-executi
Slide 24: Formal business
Formal business Items 4A to 4E: Approval for the proposed issue of securities to Directors Item 4A To consider, and if thought fit, to pass, the following as an ordinary In Favour Against Proxy Abstain resolution: Discretion “That, for the purposes of ASX Listing Rule 10.14 and for all other purpose
Slide 25: Formal business
Formal business Items 4A to 4E: Approval for the proposed issue of securities to Directors Item 4D To consider, and if thought fit, to pass, the following as an ordinary In Favour Against Proxy Abstain resolution: Discretion “That, for the purposes of ASX Listing Rule 10.14 and for all other purpose
Slide 26: Formal business
Formal business Items 5A and 5B: Approval for the proposed issue of securities to Directors in lieu of base directors’ fees Item 5A To consider, and if thought fit, to pass, the following as an ordinary In In Favour Favour Against Against Proxy Proxy Abstain Abstain resolution: Discretion Discretion
Slide 27: Formal business
Formal business Item 6: Grant of Options to the Managing Director and CEO To consider, and if thought fit, to pass, the following as an ordinary resolution: “That, for the purposes of ASX Listing Rule 10.14, sections 200B and 200E of the Corporations Act and for all other purposes, Shareholders appr
Slide 28: Formal business
Formal business Item 7: Approval of 10% Placement Facility To consider, and if thought fit, to pass, the following as a special resolution: “That, pursuant to and in accordance with Listing Rule 7.1A and for all other purposes, Shareholders approve the issue of Equity Securities up to 10% of the ful
Slide 29: Formal business
Formal business Item 8: Ratification of prior issue of Shares To consider, and if thought fit, to pass, the following as an ordinary resolution: “That, for the purposes of Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue of 19,000,000 Shares to Alpha Investment Partners Pty
Slide 30: Poll
Poll a& 4DMedical
Slide 31: 4DMedical Limited (ASX:4DX) Annual General Meeting 20 November 2024
4DMedical Limited (ASX:4DX) Annual General Meeting 20 November 2024 Copyright © 4DMedical Limited 2024 Level 7, Melbourne Connect 700 Swanston Street Melbourne, Victoria 3053 Australia www.4dmedical.com ABN 31 161 684 831